Optimal diuretic strategies in heart failure

被引:8
|
作者
Suri, Sarabjeet S. [1 ]
Pamboukian, Salpy V. [1 ]
机构
[1] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA
关键词
Heart failure (HF); diuresis; diuretic resistance; FUROSEMIDE; TOLVAPTAN;
D O I
10.21037/atm-20-4600
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Heart failure (HF) is one of the major causes of morbidity and mortality in the world. According to a 2019 American Heart Association report, about 6.2 million American adults had HF between 2013 and 2016, being responsible for almost 1 million admissions. As the population ages, the prevalence of HF is anticipated to increase, with 8 million Americans projected to have HF by 2030, posing a significant public health and financial burden. Acute decompensated HF (ADHF) is a syndrome characterized by volume overload and inadequate cardiac output associated with symptoms including some combination of exertional shortness of breath, orthopnea, paroxysmal nocturnal dyspnea (PND), fatigue, tissue congestion (e.g., peripheral edema) and decreased mentation. The pathology is characterized by hemodynamic abnormalities that result in autonomic imbalance with an increase in sympathetic activity, withdrawal of vagal activity and neurohormonal activation (NA) resulting in increased plasma volume in the setting of decreased sodium excretion, increased water retention and in turn an elevation of filling pressures. These neurohormonal changes are adaptive mechanisms which in the short term are associated with increased contractility of the left ventricular (LV) and improvement in cardiac output. But chronically, the failing heart is unable to overcome the excessive pressure and volume leading to worsening HF. The primary symptomatic management of ADHF includes intravenous (IV) diuresis to help with decongestion and return to euvolemic status. Even though diuretics have not been shown to provide any mortality benefit, they have been clinically proven to be of significant benefit in the acute decompensated phase, as well as in chronic management of HF. Loop diuretics remain the mainstay of therapy for symptomatic management of HF with use of thiazide diuretics for synergistic effect in the setting of diuretic resistance. Poor diuretic efficacy has been linked with higher mortality and increased rehospitalizations.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: An analysis from Diuretic Optimization Strategies in Acute Heart Failure
    Shah, Ravi V.
    McNulty, Steven
    O'Connor, Christopher M.
    Felker, G. Michael
    Braunwald, Eugene
    Givertz, Michael M.
    AMERICAN HEART JOURNAL, 2012, 164 (06) : 862 - 868
  • [22] Diuretic Combination Therapy in Acute Heart Failure: An Updated Review
    Villaschi, Alessandro
    Pellegrino, Marta
    Condorelli, Gianluigi
    Chiarito, Mauro
    CURRENT PHARMACEUTICAL DESIGN, 2024, 30 (33) : 2597 - 2605
  • [23] The Importance of the Nephrologist in the Treatment of the Diuretic-Resistant Heart Failure
    Petho, Akos Geza
    Tapolyai, Mihaly
    Browne, Maria
    Fulop, Tibor
    Orosz, Petronella
    Szabo, Reka P.
    LIFE-BASEL, 2023, 13 (06):
  • [24] Toward quantification of loop diuretic responsiveness for congestive heart failure
    Oyama, Mark A.
    Adin, Darcy
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2023, 37 (01) : 12 - 21
  • [25] The Management of Acute Heart Failure and Diuretic Therapy
    Somberg, John C.
    Molnar, Janos
    AMERICAN JOURNAL OF THERAPEUTICS, 2009, 16 (01) : 93 - 97
  • [26] Empagliflozin in Heart Failure Diuretic and Cardiorenal Effects
    Griffin, Matthew
    Rao, Veena S.
    Ivey-Miranda, Juan
    Fleming, James
    Mahoney, Devin
    Maulion, Christopher
    Suda, Nisha
    Siwakoti, Krishmita
    Ahmad, Tariq
    Jacoby, Daniel
    Riello, Ralph
    Bellumkonda, Lavanya
    Cox, Zachary
    Collins, Sean
    Jeon, Sangchoon
    Turner, Jeffrey M.
    Wilson, F. Perry
    Butler, Javed
    Inzucchi, Silvio E.
    Testani, Jeffrey M.
    CIRCULATION, 2020, 142 (11) : 1028 - 1039
  • [27] Implantable Diuretic Pump for Heart Failure Management
    Yassin, Ahmed S.
    AMERICAN JOURNAL OF THERAPEUTICS, 2020, 27 (03) : E320 - E322
  • [28] Management of congestion and diuretic resistance in heart failure
    Regolisti, Giuseppe
    Antoniotti, Riccardo
    Pastorini, Guido
    Fani, Filippo
    Fiaccadori, Enrico
    NEPHROLOGY @ POINT OF CARE, 2016, 2 (01): : E73 - E87
  • [29] Prevalence and outcome of diuretic resistance in heart failure
    Joan-Carles Trullàs
    Jesús Casado
    Jose-Luís Morales-Rull
    Francesc Formiga
    Alicia Conde-Martel
    Raúl Quirós
    Francisco Epelde
    Álvaro González-Franco
    Luis Manzano
    Manuel Montero-Pérez-Barquero
    Internal and Emergency Medicine, 2019, 14 : 529 - 537
  • [30] Diuretic Therapy in Heart Failure - Current Approaches
    Casu, Gavino
    Merella, Pierluigi
    EUROPEAN CARDIOLOGY REVIEW, 2015, 10 (01) : 42 - 47